Viewing Opinion | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

2017-08-10

Opinion for Bristol Myers Squibb (BMY-N)

Signal Price Bias Subject Owned
TOP PICK $56.590 CAUTIOUS NORTH AMERICAN Yes

It represents tremendous value for patient investors.  Over 3-4 years there is tremendous value in the pipeline of drugs.  They have the best franchise.  There are activists involved.  It could be an M&A target.  (Analysts’ target: $58.00).

Robert Lauzon
Deputy Chief Investment Officer, Middlefield Capital Corporation

No Comments.


You must be logged in to comment.